|
UROLOGICAL
ONCOLOGY
Guidelines
on TaT1 (Non-muscle Invasive) Bladder Cancer
Oosterlinck W, van der Meijden A, Sylvester R, Bohle A, Rintala E, Solsona
Narvón E, Lobel B
European Association of Urology
http://www.uroweb.org/files/uploaded_files/guidelines/05%20TaT1%20Bladder%20Cancer.pdf
No
abstract avilable
-
Editorial Comment
These guideline represent and evolutional development from the “old”
EAU bladder cancer guidelines, which were well received worldwide. They
incorporate recommendations for such major steps in superficial bladder
cancer treatment as postoperative single shot instillation with chemotherapy
and maintenance therapy with BCG.
The most important information, which led to these steps forward, came
from recently published metaanalyses, which were prepared in close cooperation
predominantly from members of the guidelines group.
Specifically, the following changes appear as of highest importance
and are commented below. Guidelines for superficial and invasive bladder
cancer are generated from different groups and are distinct.
Use of histological classification - However, until the 2004 WHO classification
has been validated by more clinical trials, tumors should be graded
according to both the 1973 and the 2003 WHO classification.
Fluorescence cystoscopy - This investigational method has not yet been
implemented on a regular basis in daily practice.
Second resection is recommended in most intermediate and all high-risk
tumors.
Single-shot postoperative instillation of chemotherapy is strongly recommended.
Intravesical BCG is superior to intravesical chemotherapy in reducing
recurrences and is the only drug to interfere with progression of SBC.
BCG immunotherapy is indicated in intermediate risk and high-risk bladder
cancer. The use of maintenance therapy of at least 1 year is strongly
recommended.
An algorithm for predicting tumor recurrence and progression is extensively
provided in these guidelines.
Dr.
Andreas Bohle
Professor of Urology
HELIOS Agnes Karll Hospital
Bad Schwartau, Germany |